Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 33,144 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Bipolar Disorder, Bipolar Depression, Depression
Interventions: quetiapine fumarate (Seroquel), paroxetine, mood stabilizing activity; Drug · Behavioral
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 676 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 28
States / cities: Phoenix, Arizona • Little Rock, Arkansas • National City, California + 25 more

Conditions: Influenza
Interventions: Intravenous hyperimmune immunoglobulin (Flu-IVIG), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 11
States / cities: San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more

Conditions: Premature Birth, Stress
Interventions: massage therapy, Sham; Other
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 28 Weeks to 33 Weeks
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Mild Cognitive Impairment
Interventions: Tailored Rhythmic Lighting Intervention, Placebo Rhythmic Lighting Intervention; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 55 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Menands, New York • New York, New York

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo, Avonex®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Helicobacter Pylori Infection
Interventions: BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE, MATCHING PLACEBO; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Nonalcoholic Steatohepatitis
Interventions: Placebo, Cenicriviroc; Drug
Lead sponsor: Tobira Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,778 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 204
States / cities: Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 144 more

Conditions: Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Neuromuscular Diseases, Neurodegenerative Diseases, Spinal Cord Diseases, TDP-43 Proteinopathies, Nervous System Diseases, Central Nervous System Diseases
Interventions: AMX0035, Placebo; Drug · Other
Lead sponsor: Amylyx Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 25
States / cities: Phoenix, Arizona • Orange, California • San Francisco, California + 21 more

Conditions: HIV Infections
Interventions: CPI-1189; Drug
Lead sponsor: Centaur Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: San Diego, California • Chicago, Illinois • Baltimore, Maryland + 3 more

Conditions: Heterozygous Familial Hypercholesterolemia
Interventions: lerodalcibep; Drug
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Reldesemtiv, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 489 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 30 more

Conditions: Influenza
Interventions: Subjects were administered NasoVAX high dose; Drug
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: HSV
Interventions: Benzoyl Peroxide 10% Bar, Placebo; Drug · Other
Lead sponsor: Greg Bew; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Evans, Georgia

Conditions: Obesity
Interventions: Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Covina, California • Walnut Creek, California • New Haven, Connecticut + 7 more

Conditions: Overactive Bladder, Constipation, Lower Urinary Tract Symptoms
Interventions: Baclofen, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 64 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy
Interventions: Setria performance blend, Placebo; Dietary Supplement
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 20 Years to 30 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Recurrent Herpes Labialis
Interventions: Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 2,020 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Culver City, California

Conditions: Crohn Disease
Interventions: infliximab infusion; AZA placebo caps, infliximab (IFX) infusion; azathioprine (AZA) caps, infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Biological · Other · Drug
Lead sponsor: Centocor Ortho Biotech Services, L.L.C.; Industry
Eligibility: 21 Years to 99 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 51
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 48 more

Conditions: Nicotine Dependence, Nicotine Withdrawal
Interventions: Bupropion, Varenicline; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Vasomotor Symptoms, Menopausal Symptoms
Interventions: Estetrol, Placebo, Progesterone; Drug
Lead sponsor: Estetra; Industry
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 1,570 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 65
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 52 more

Conditions: Osteoarthritis of the Knee
Interventions: 4 mL injection of Ampion, 4 mL Injection of Placebo; Biological · Drug
Lead sponsor: Ampio Pharmaceuticals. Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Englewood, Colorado

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Atomoxetine hydrochloride, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 445 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 27
States / cities: Los Angeles, California • Rolling Hills Est., California • Spring Valley, California + 24 more

Conditions: Insulin Sensitivity
Interventions: Eritoran, D5W; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Parkinson Disease
Interventions: Hydrogen, Placebo oral tablet; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Stony Brook, New York

Search by objective public record fields.

Seroquel in Bipolar Depression Versus SSRI

Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)

Effects of Massage on the Immune System of Preterm Infants

Rhythmic Light Therapy for Alzheimer's Disease Patients

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

Helicobacter Pylori and Body Iron in Adults

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Study of the Safety and Immunogenicity of NasoVAX Extension

Evaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen

Setria Performance Blend Supplementation

A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

A Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis

Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease